In patients with MSS GC, LATS1/2 signaling pathway activation was also correlated with an adverse prognosis, indicating that LATS1/2 activation might suppress the antitumor effect of CD8+ T cells and activate immunosuppressive effects in FOXP3+ Treg cells. The gene discussed is FOXP3; the disease is Marinesco-Sjogren syndrome.